Teralys Capital has committed $50 million to the first close of CTI II, the second life sciences fund of Canadian venture capital firm CTI Life Sciences. As reported by peHUB Canada, the firm raised $134 million of a targeted $150 million for its fund. Other investors in CTI II included the Caisse de dépôt et placement du Québec, Fonds de solidarité FTQ and BDC Capital. The Montréal-based Teralys last November secured $279 million in the initial close of its second investment vehicle, Teralys Capital Innovation Fund.
Teralys Capital reaffirms its commitment to life sciences with a significant investment in CTI Life Sciences II
MONTREAL, Jan. 15, 2015 /CNW Telbec/ – Teralys Capital, Canada’s largest fund manager specialized in innovation, is proud to announce a significant $50 million commitment in the $135 million first closing of Montreal-based CTI Life Sciences II (“CTI II”), alongside commitments from Caisse de dépôt et placement du Québec, the Fonds de solidarité FTQ, the Government of Canada Venture Capital Action Plan (“VCAP”), and other investors.
CTI II will invest predominantly in syndicated biotherapeutics opportunities, seeking to build great companies that develop assets at the pre-clinical to early clinical phase. Concurrent with the closing of its second fund, CTI has expanded its team and opened a presence in the Northeast USA. Building on the success of its initial fund, CTI II now has access to a larger fund and an international network to successfully pursue its investment strategy.
Life sciences is a sector of critical importance to Teralys Capital. Over the past few years, Teralys has invested in a wide range of investment managers and business models, which reflect the diversity of investment opportunities in this sector and the need for various types of capital offerings to entrepreneurs. Teralys believes in building great companies and supporting them across all stages of their development. More recently, Teralys also announced the initial closing of the Teralys Capital Innovation Fund, which is the only fund of funds selected by VCAP for its specialized expertise in life sciences as a part of Teralys’ investment strategy in all innovation sectors. Teralys also continues to actively serve on various industry and public policy initiatives in this sector in Quebec, across Canada and selectively at the international level.
“Teralys is proud to continue expanding its local support in life sciences. CTI II, our latest investment in this field, will contribute to the building of companies based on great entrepreneurs and top medical innovations”, said Cédric Bisson, partner at Teralys Capital.
About Teralys Capital
Teralys Capital is a fund manager financing private venture capital funds investing in innovative businesses in information technologies, life sciences, and clean or industrial innovations. With more than $1.5 billion in assets under management across two venture capital funds of funds and a management mandate for two additional portfolios of funds, Teralys is the largest investor focused on innovation in Canada. Teralys has been supported since inception in 2009 by its many partners including the Caisse de dépôt et placement du Québec, the Fonds de solidarité FTQ and Investissement Québec. Visit www.teralyscapital.com for more information.
SOURCE Teralys Capital
For further information: Teralys Capital, Eric Legault, Managing partner, (514) 509-2082, email@example.com
Photo courtesy of Shutterstock